ResearchSafe

Novo Nordisk wins Dutch injunction against compounded semaglutide nasal spray

Posted by sleep_coastal in Research & News - 4 points, 5 comments.

https://pharmaphorum.com/news/novo-nordisk-wins-netherlands-glp-1-compounding-lawsuit

Novo Nordisk just got a Dutch court to shut down a compounding pharmacy that was making a nasal spray version of semaglutide. The court ruled the pharmacy exemption does not cover this kind of formulation. Pharmaphorum has the story.

This one matters to us more than people might think. Compounding pharmacies have been the backdoor for a lot of peptide access, and Novo is clearly going after formulations that stray from standard injectable prep. Anecdotally, I have followed the GLP-1 compounding space pretty closely, and the nasal spray angle always seemed like a stretch to me. Bioavailability through nasal mucosa for a peptide that large is questionable at best. So I am not exactly heartbroken about this specific formulation getting blocked. But the precedent is the real story. If courts start narrowing pharmacy exemptions across Europe, it could ripple into how other compounded peptides get handled too.

Anyone else watching whether this pushes more people toward telehealth injectable programs, or do you think the compounding fight stays limited to GLP-1s?

Comments

  • early_hrv: I've been kinda watching this unfold from a distance and honestly the nasal spray thing always baffled me because semaglutide is a big peptide and getting that through nasal mucosa in any meaningful amount just seemed like wishful thinking from the start, so yeah I'm with you on not being heartbroken about that specific one getting shut down. But the precedent angle is what keeps me up a little. I've seen how these legal fights tend to creep outward once there's a ruling someone can point to. G
  • sleep_coastal: Yeah the creeping outward thing is exactly what bugs me. You said it well, once there is a ruling someone can point to, it becomes a template. GLP-1s are the deep-pocket target right now but the language in these rulings rarely stays scoped to one drug class. If the Dutch court framed the pharmacy exemption narrowly around formulation type rather than the drug itself, that wording could get cited for BPC-157, TB-500, anything compounded that is not a standard prep. Anecdotally, I have already s
  • tinkerer_rational: Yeah that's basically my worry too. The nasal spray was always dubious, fine, whatever. But once you get a court saying the compounding exemption doesn't cover "novel formulations," that language is vague enough to scare pharmacies away from other stuff too. Could ripple into BPC, TB-500, things that aren't even GLP-1s... Gonna be interesting to watch.
  • sleep_coastal: Exactly, the "novel formulation" language is the part that bugs me. BPC-157 and TB-500 are already in a gray zone legally in a lot of places. If pharmacies read this ruling and start self-censoring because they are spooked, we lose access to stuff that has nothing to do with GLP-1s. Anecdotally, I have already seen a couple of European compounding sites quietly drop peptide listings over the last year. Hard to say if this ruling is the cause or just part of a broader chill. Gonna watch how Germ
  • miles_codes: I’ve noticed a few US compounding sites pulling semaglutide troches and sublingual drops after similar warnings, even though those aren’t nasal sprays. It feels like pharmacies are erring on the side of caution across the board, which could spill over into other peptides like BPC‑157 if they start seeing any novel delivery as risky.

Community discussion - research and educational context only. Not medical advice.